56 results
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
but have compared the published data for Avacopan to data from our Phase 1 clinical trial of INF904. For the purpose of conducting pre-clinical studies
6-K
EX-99.2
IFRX
InflaRx N.V.
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
the published data for Avacopan to data from our Phase 1 clinical trial of INF904. For the purpose of conducting pre-clinical studies (hamster neutropenia study
424B5
IFRX
InflaRx N.V.
12 Jul 23
Prospectus supplement for primary offering
12:00am
to such information. Such period shall not exceed the term stipulated by Dutch law and/or DCGC for that purpose. If invoked, the board of directors must use … -making; or
other defensive measures, having the same purpose, nature and scope as the cooling-off period, have been activated during the cooling-off
F-3
0z6ppu9s0j
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.2
3y12bengyk0obxvb7
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
lm0s3
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.3
cggobdbyp
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.2
m5mn60nsakbh pb
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-1.1
immesd052
13 Apr 23
Current report (foreign)
4:01pm
424B5
g3ueeajyh0yyeuzw7
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
s8kulke7gbeuwg23sbv
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-10.1
9bd 3spie81lx9lk
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.1
gqalb d9csauk45
6 Jul 22
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
8:30am
6-K
EX-99.2
c42sin989qasvgc6h
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.1
9kmiz7 dhf
19 Oct 21
Current report (foreign)
7:30am